Showing 5961-5970 of 9846 results for "".
- FDA Approves StrataGraft for the Treatment of Adults with Thermal Burnshttps://practicaldermatology.com/news/fda-approves-stratagraft-for-the-treatment-of-adults-with-thermal-burns/2460839/The U.S. Food and Drug Administration approved StrataGraft for the treatment of adult deep partial thickness burns. "Serious burns can be an incredibly difficult injury to treat and can adversely affect more than just the skin. The goal of burn management is to help the patient ret
- AAD Survey: Only a Third of Americans are Concerned about Skin Cancer Despite Nearly 70% Having at Least One Risk Factorhttps://practicaldermatology.com/news/aad-survey-only-a-third-of-americans-are-concerned-about-skin-cancer-despite-nearly-70-having-at-least-one-risk-factor/2460836/Despite skin cancer being the most common cancer in the U.S., only about one-third of adults are concerned about developing the disease, even though nearly 70 percent say they have at least one risk factor for skin cancer, according to a new American Academy of Dermatology (AAD) survey.
- Nurx Adds Rosacea Care to List of Serviceshttps://practicaldermatology.com/news/nurx-adds-rosacea-care-to-list-of-services/2460832/Nurx, now includes rosacea treatment in its at-home dermatology services. The service consists of a consultation with a Nurx medical provider, a personalized treatment plan for rosacea, home delivery of medication, and ongoing care. The expansion builds on the successful launch of Nurx&
- FDA Approves Expanded Use of the RECELL System for Extensive Burns and Pediatric Patientshttps://practicaldermatology.com/news/fda-approves-expanded-use-of-the-recell-system-for-extensive-burns-and-pediatric-patients/2460831/The U.S. Food and Drug Administration (FDA) approved expanded use of the RECELL System in combination with meshed autografting for the treatment of all sizes of acute full-thickness thermal burn wounds for both pediatric and adult patients. Specifically, RECELL is now in
- FDA Grants Breakthrough Device Status to Alpha DaRT for SCChttps://practicaldermatology.com/news/fda-grants-breakthrough-device-status-to-alpha-dart-for-scc/2460829/The U.S. Food and Drug Administration (FDA) granted Alpha Tau Medical a Breakthrough Device Designation for Alpha DaRT for the treatment of squamous cell carcinoma (SCC) of the skin and oral cavity without curative standard of care. Alpha Tau submitted data to the FDA supporting this de
- Allergan Aesthetics, Botox Cosmetic Unveil "See Yourself" Campaign with Real Stories from Real Patientshttps://practicaldermatology.com/news/allergan-aesthetics-botox-cosmetic-unveil-see-yourself-campaign-with-real-stories-from-real-patients/2460828/Allergan Aesthetics is launching "See Yourself," a new campaign featuring documentary-style shorts that tell the stories of real Botox Cosmetic patients. Watch 'See Yourself' shorts at www.BotoxCosmetic.com and @Bot
- EULAR: Data Show Benefit of Tremfya in PsA After Anti-TNF Failurehttps://practicaldermatology.com/news/eular-day-shown-benefit-of-tremfya-in-psa-after-anti-tnf-failure/2460834/New efficacy and safety data presented at the EULAR E-Congress suggest that first-in-class Tremfy (guselkumab) benefits adult patients with active PsA who had inadequate response or intolerance to TNF inhibitors. Trem
- Sofwave Medical Goes Public on the Tel Aviv Stock Exchangehttps://practicaldermatology.com/news/sofwave-medical-goes-public-on-the-tel-aviv-stock-exchange/2460824/Sofwave Medical made its initial public offering (IPO) on the Tel Aviv Stock Exchange (TASE) and raised $50 million at a pre-money valuation of ~$200 million. The IPO was led by Barak Capital Underwriters. The company has developed Synchronous Ul
- Dermavant Submits NDA for Tapinarof for PsOhttps://practicaldermatology.com/news/dermavant-submits-nda-for-tapinarof-for-pso/2460820/Dermavant Sciences has submitted a New Drug Application (NDA) to the FDA for tapinarof for the treatment of mild, moderate, and severe plaque psoriasis in adult patients. Tapinarof is a novel, therapeutic aryl hydrocarbon receptor modulating agent, in development as a once-daily,
- AstraZeneca's Anifrolumab Shows Benefit for Skin, Joint Symptoms of Lupushttps://practicaldermatology.com/news/astrazenecas-anifrolumab-shows-benefit-for-skin-joint-symptoms-of-lupus/2460819/Anifrolumab is consistently associated with improvements in both skin rash and arthritis across three different disease measures in patients with moderate to severe systemic lupus erythematosus (SLE), results of a new post-hoc analysis of pooled data from the TULIP phase 3 clinical trials show. T